Minerva Neurosciences Inc (NASDAQ:NERV) Director Purchases $18,900.00 in Stock
Minerva Neurosciences Inc (NASDAQ:NERV) Director William F. Doyle purchased 1,800 shares of the stock in a transaction dated Monday, September 17th. The shares were purchased at an average price of $10.50 per share, with a total value of $18,900.00. Following the completion of the acquisition, the director now owns 12,011 shares of the company’s stock, valued at $126,115.50. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.
NASDAQ NERV traded down $0.17 on Friday, reaching $9.75. The company’s stock had a trading volume of 199,907 shares, compared to its average volume of 188,389. Minerva Neurosciences Inc has a twelve month low of $4.80 and a twelve month high of $12.95. The company has a market capitalization of $486.62 million, a price-to-earnings ratio of -9.03 and a beta of 1.60.
Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. On average, sell-side analysts anticipate that Minerva Neurosciences Inc will post -1.39 EPS for the current year.
A number of research analysts have recently commented on the stock. BidaskClub cut shares of Minerva Neurosciences from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. ValuEngine raised shares of Minerva Neurosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 23rd. Finally, Citigroup boosted their target price on shares of Minerva Neurosciences to $19.00 in a research note on Friday, August 3rd.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.
Featured Story: Day Trading
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.